Afaxys
Private Company
Total funding raised: $75M
Overview
Afaxys is a specialized generic drug company with a clear social mission to improve access to affordable reproductive healthcare. It operates as a commercial-stage enterprise, marketing a portfolio of AB-rated generic oral contraceptives, the over-the-counter emergency contraceptive EContra One-Step, and the contraceptive patch Twirla (as a promotional partner). The company's core strategy involves partnering with federally qualified health centers, clinics, and public health providers to ensure a stable supply of essential medications for underserved populations, positioning itself as a key supplier in this niche segment of the generic drug market.
Technology Platform
Specialized commercial and distribution model for generic pharmaceuticals focused on public health clinics and safety-net providers, ensuring reliable supply and stable pricing.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Afaxys competes with large generic pharmaceutical companies (e.g., Teva, Viatris) that market similar contraceptive products broadly, but it differentiates through its focused mission, clinic-centric service model, and commitment to stable pricing. Its primary competition for clinic contracts likely comes from other specialty distributors and the generic arms of larger drug companies.